Sarepta Therapeutics (NASDAQ:SRPT) had its price objective raised by Morgan Stanley from $165.00 to $220.00 in a research note issued to investors on Tuesday morning, BenzingaRatingsTable reports. They currently have an overweight rating on the biotechnology company’s stock.
A number of other equities analysts have also recently commented on SRPT. ValuEngine cut shares of WideOpenWest from a hold rating to a sell rating in a report on Friday, June 28th. Credit Suisse Group set a $60.00 target price on shares of Oracle and gave the company a buy rating in a report on Monday, March 11th. Cowen reaffirmed a buy rating and issued a $77.00 target price on shares of Centene in a report on Sunday, March 31st. Citigroup set a $6.00 price objective on shares of Solid Biosciences and gave the company a hold rating in a research note on Thursday, May 16th. Finally, Piper Jaffray Companies reissued a hold rating on shares of Seattle Genetics in a research note on Thursday, March 28th. One equities research analyst has rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. Sarepta Therapeutics currently has an average rating of Buy and an average price target of $206.82.
Shares of Sarepta Therapeutics stock opened at $154.24 on Tuesday. The firm has a fifty day simple moving average of $130.83. The firm has a market cap of $11.20 billion, a PE ratio of -28.25 and a beta of 2.12. Sarepta Therapeutics has a 12 month low of $95.21 and a 12 month high of $165.87. The company has a quick ratio of 11.15, a current ratio of 12.17 and a debt-to-equity ratio of 0.35.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($1.07) EPS for the quarter, beating analysts’ consensus estimates of ($2.05) by $0.98. The business had revenue of $87.01 million for the quarter, compared to analysts’ expectations of $86.92 million. Sarepta Therapeutics had a negative net margin of 124.66% and a negative return on equity of 36.26%. On average, equities analysts expect that Sarepta Therapeutics will post -4.04 EPS for the current year.
In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,200,000.00. Following the sale, the director now directly owns 21,717 shares in the company, valued at approximately $2,606,040. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.60% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp increased its holdings in shares of Sarepta Therapeutics by 104.7% in the fourth quarter. Bank of New York Mellon Corp now owns 570,668 shares of the biotechnology company’s stock worth $62,277,000 after purchasing an additional 291,823 shares during the period. Raymond James Financial Services Advisors Inc. grew its position in Sarepta Therapeutics by 7.3% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 12,512 shares of the biotechnology company’s stock worth $1,365,000 after acquiring an additional 852 shares in the last quarter. Northern Trust Corp grew its position in Sarepta Therapeutics by 6.5% in the fourth quarter. Northern Trust Corp now owns 318,287 shares of the biotechnology company’s stock worth $34,734,000 after acquiring an additional 19,473 shares in the last quarter. Great West Life Assurance Co. Can grew its position in Sarepta Therapeutics by 7.6% in the fourth quarter. Great West Life Assurance Co. Can now owns 7,476 shares of the biotechnology company’s stock worth $787,000 after acquiring an additional 528 shares in the last quarter. Finally, Bessemer Group Inc. grew its position in Sarepta Therapeutics by 7,143.5% in the fourth quarter. Bessemer Group Inc. now owns 1,666 shares of the biotechnology company’s stock worth $183,000 after acquiring an additional 1,643 shares in the last quarter. Institutional investors own 94.36% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Read More: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.